Pharmacokinetics-Pharmacodynamics of Antimicrobial Therapy: It's Not Just for Mice Anymore

Since the advent of the modern era of antimicrobial chemotherapy in the 1930s, animal infection models have allowed for the in vivo evaluation of antimicrobial agents for the treatment of experimentally induced infection. Today, animal pharmacokinetic-pharmacodynamic (PK-PD) infection models serve a...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 2007-01, Vol.44 (1), p.79-86
Main Authors: Ambrose, Paul G., Bhavnani, Sujata M., Rubino, Christopher M., Louie, Arnold, Gumbo, Tawanda, Forrest, Alan, Drusano, George L.
Format: Article
Language:English
Subjects:
Animals
Anti-Bacterial Agents - pharmacokinetics
Anti-Bacterial Agents - therapeutic use
Antibacterial agents
Antibacterials
Antibiotic resistance
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antimicrobial Resistance
Antimicrobials
Area Under Curve
Bacteremia - drug therapy
Bacteremia - microbiology
Bacterial Infections - drug therapy
Bacterial Infections - microbiology
Biological and medical sciences
Chemotherapy
Clinical trials
Community-Acquired Infections - drug therapy
Community-Acquired Infections - microbiology
Disease Models, Animal
Dosage
Drug design
Drug resistance
Fluoroquinolones
Humans
Infections
Medical sciences
Medical treatment
Mice
Penicillin
Pharmacology
Pharmacology. Drug treatments
Respiratory Tract Infections - drug therapy
Respiratory Tract Infections - microbiology
Skin Diseases, Bacterial - drug therapy
Skin Diseases, Bacterial - microbiology
Time dependence
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Since the advent of the modern era of antimicrobial chemotherapy in the 1930s, animal infection models have allowed for the in vivo evaluation of antimicrobial agents for the treatment of experimentally induced infection. Today, animal pharmacokinetic-pharmacodynamic (PK-PD) infection models serve as a cornerstone of the preclinical assessment process for antibacterial agents and dose and dosing interval selection, as decision support for setting in vitro susceptibility breakpoints, and, finally, for the evaluation of the meaning of in vitro resistance. Over the past 15 years, considerable PK-PD data have been derived from infected patients for many classes of antimicrobial agents. These data provide the opportunity to confirm knowledge gained from animal PK-PD infection models.
ISSN:1058-4838
1537-6591
DOI:10.1086/510079